Risk and severity of injection site reactions and flu-like symptoms in patients treated with non-pegylated and pegylated subcutaneous interferon beta drugs

Trial Profile

Risk and severity of injection site reactions and flu-like symptoms in patients treated with non-pegylated and pegylated subcutaneous interferon beta drugs

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs Interferon beta-1a (Primary) ; Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Feb 2016 New trial record
    • 10 Oct 2015 Results (n=25) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top